Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01349 FUDANZHANGJIANG
RTNominal unchange3.990 0.000 (0.000%)
Others

15/10/2021 11:19

Fudan-Zhangjiang (01349) gets acceptance notice from NMPA

[ET Net News Agency, 15 October 2021] Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,
Ltd. (01349) said the company has received the acceptance notice issued by the National
Medical Products Administration of the PRC (NMPA). The investigational new drug (IND)
application for Phase II clinical trial of Aminolevulinic Acid Hydrochloride Topical
Powder on mild-tomoderate severity Actinic Keratosis (AK) of the face and scalp has been
accepted.
AK, known as photolinear keratosis, solar keratosis and senile keratosis, is a
precancerous skin lesion caused by atypical epidermal keratinocyte proliferation. It
mostly occurs in the exposed parts such as face, scalp or dorsum of the hands, and mostly
occurs in middle-aged and elderly people. (RC)

Remark: Real time quote last updated: 26/11/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.